WHO launches first ever rsv vaccine for babies; what parents need to know now

Considering the health threat posed by Respiratory Syncytial Virus (RSV) in infants, the World Health Organization (WHO) urges a rollout of either the RSVpreF maternal immunisation or the monoclonal antibody treatment, nirsevimab, to shield infants from severe infection. RSV has long been overlooked, despite causing millions of hospitalisations and nearly 100,000 deaths in children under five each year. Now, for the first time, the World Health Organisation has issued global guidance recommending immunisation to protect infants from this serious and often deadly virus.

The new WHO position paper, released on 30 May 2025, introduces two promising ways to protect infants: a maternal vaccine and a monoclonal antibody injection. These aren’t just technical advances; they could be lifesavers, particularly in low- and middle-income countries, where medical access is limited and RSV mortality is tragically high. With these tools, families now have hope in the fight against a virus that has quietly taken a devastating toll.

What is RSV: RSV (Respiratory Syncytial Virus) is a highly contagious virus that infects the lungs and airways. It spreads easily through sneezing, coughing, and close contact. While it often mimics a cold, RSV can quickly become dangerous for babies, especially those under six months, and the elderly or immunocompromised.

Signs your baby might have more than just a cold: RSV often begins like a typical cold, with symptoms such as a runny nose, mild fever, sneezing, coughing, irritability, and difficulty feeding. However, parents should watch closely for more serious signs like fast or laboured breathing, wheezing, chest retractions, bluish lips or fingers, or long pauses in breathing (apnoea). These require urgent medical attention.